May 14, 2020
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year
May 11, 2020
Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 05, 2020
Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion
May 01, 2020
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 23, 2020
Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020
Apr 07, 2020
Portola Pharmaceuticals Announces the Establishment of a Permanent J-code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020
Apr 01, 2020
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 16, 2020
Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
Mar 05, 2020
New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Feb 26, 2020
Portola Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
Feb 24, 2020
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Feb 12, 2020
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020
Feb 03, 2020
Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer
Jan 09, 2020
Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million
Dec 23, 2019
Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020
Dec 17, 2019
Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke
Dec 08, 2019
Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies
Nov 06, 2019
Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology (ASH) Annual Meeting
Nov 05, 2019
Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Nov 01, 2019
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)